ORPHA:89936
X-linked hypophosphatemia
Also known as: X-linked hypophosphatemic rickets · XLH
Publications
5,995
93.2th percentile
Trials
29
Interventional, condition-specific
Researchers
1,149
Distinct authors in sample
Gene link
PHEX
Definitive
Readiness
6/6
Stages with a signal
Clinical definition (Orphanet)
A rare renal phosphate-wasting disorder characterized by hypophosphatemia, rickets and/or osteomalacia, and diminished growth.
How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0010619
- OMIM:307800
- UMLS:C0733682
- NCIT:C85234
Additional Mondo synonyms (7)
X-linked dominant hypophosphatemic rickets · X-linked hereditary hypophosphatemic rickets · hereditary hypophosphatemic rickets, X-linked · hypophosphatemic rickets, X-linked · hypophosphatemic rickets, X-linked dominant, X-linked dominant · rickets, vitamin D-resistant · vitamin D-resistant rickets, X-linked
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
6/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedPresent
Definitive — PHEX
- LiteraturePresent
5,995 matched papers (3,676 in last 10 years) Source
- Phenotype characterisedPresent
85 HPO annotations (e.g. Chiari type I malformation; Sacroiliac joint synovitis; Elevated circulating fibroblast growth factor 23 concentration) Source
- Animal modelPresent
50 genotype models (Mus musculus) Source
- Orphan designationPartial
1 FDA designation (none yet with FDA orphan-indication approval) — e.g. burosumab-twza Source
- Interventional trialPresent
29 matched on ClinicalTrials.gov (2 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (PHEX).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
85
Associated phenotypes · MONDO:0010619
- Chiari type I malformation
- Sacroiliac joint synovitis
- Elevated circulating fibroblast growth factor 23 concentration
- Renal phosphate wasting
- Hypophosphatemia
Showing 5 of 85 — open Monarch for the full list.
Animal models (Monarch / Alliance)
50
Model associations linked to this Mondo ID
- PhexMhdabap024/Y [background:] C3HeB/FeJ-PhexMhdabap024·MGI:6198725·Mus musculus
- PhexMhdabap024/Phex+ [background:] C3HeB/FeJ-PhexMhdabap024·MGI:6198726·Mus musculus
- Gy/Y [background:] involves: C3H/Sn * C57BL/6Ei·MGI:3037661·Mus musculus
- Fgf23tm1Sliu/Fgf23+ PhexHyp/Y [background:] involves: 129S/SvEv * C57BL/6·MGI:3653482·Mus musculus
- Fgf23tm1Blan/Fgf23+ PhexHyp/Y [background:] Not Specified·MGI:3512461·Mus musculus
- PhexMhdabap024/PhexMhdabap024 [background:] C3HeB/FeJ-PhexMhdabap024·MGI:5425687·Mus musculus
- PhexHyp/Phex+ [background:] B6.Cg-PhexHyp/J·MGI:3764685·Mus musculus
- PhexSka1/Phex+ [background:] C57BL/6-PhexSka1·MGI:4450916·Mus musculus
- PhexHyp/Y [background:] B6.Cg-PhexHyp/J·MGI:3764489·Mus musculus
- Fgf23tm1Sliu/Fgf23tm1Sliu PhexHyp/Y [background:] involves: 129S/SvEv * C57BL/6·MGI:3653483·Mus musculus
- PhexHyp-2J/Phex+ [background:] C57BL/6-PhexHyp-2J/J·MGI:3037641·Mus musculus
- PhexSka1/Y [background:] C57BL/6-PhexSka1·MGI:4450917·Mus musculus
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
1
Designation · no FDA orphan-indication approval yet
- FDA burosumab-twza (Crysvita)X-Linked Hypophosphatemia vitamin d-resistant rickets X-Linked Hypophosphatemia · 2009-12-14
Sources: FDA OOPD · EMA orphan designations
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
5,995
5,995 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
5,995 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
3,676 in the last 10 years · medium confidence · 93.2th percentile (publications denominator)
Phrase hits: 2,705 · MeSH hits: 0
Who's working on it?
1,149
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Fukumoto S11 papers · 2026
Department of Medicine, Tamaki-Aozora Hospital, 779-3125 Tokushima, Japan.
Papers in Europe PMC - 02Imel EA10 papers · 2026
Department of Medicine and Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Papers in Europe PMC - 03Brandi ML9 papers · 2026
Donatello Bone Clinic, Villa Donatello Hospital, Florence, Italy.
Papers in Europe PMC - 04Carpenter TO9 papers · 2026
Yale University School of Medicine, Department of Pediatrics and Department of Orthopaedics and Rehabilitation, New Haven, CT, United States of America.
Papers in Europe PMC - 05Ozono K9 papers · 2026
Center for Promoting Treatment of Intractable Diseases, ISEIKAI International General Hospital, 4-14 Minamiogimachi, Kita-ku, Osaka-shi, Osaka, 530-0052, Japan.
Papers in Europe PMC - 06Baroncelli GI8 papers · 2026
Pediatric and Adolescent Endocrinology, Division of Pediatrics, Department of Obstetrics, Gynecology and Pediatrics, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Papers in Europe PMC - 07Ito N7 papers · 2026
Osteoporosis Center, The University of Tokyo Hospital, Tokyo 113-8655, Japan.
Papers in Europe PMC - 08Li Z7 papers · 2026
Kyowa Kirin, Inc., 510 Carnegie Center Dr. Suite 600, Princeton, NJ, 08540, USA.
Papers in Europe PMC - 09Linglart A7 papers · 2026
Paris Saclay University, INSERM, AP-HP, Bicêtre Paris Saclay Hospital, Le Kremlin Bicêtre Cedex, France.
Papers in Europe PMC - 10Michigami T7 papers · 2026
Department of Bone and Mineral Research, Osaka Women's and Children's Hospital, Izumi, Japan.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
29
interventional trials for this specific condition
29 interventional trials matched this specific condition name; 2 currently recruiting in our sample.
Data as of 11 September 2026 · last trial check 28 July 2026
29 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 95.9th percentile).
medium confidence · 95.9th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
29 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06525636·RECRUITING·A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia
Not reviewed·Conditions: X-linked Hypophosphatemia·Matched via name phrase
- NCT06921720·RECRUITING·Phosphorus-31 Spectroscopy in Phosphate Diabetes
Not reviewed·Conditions: Phosphate Diabetes · X-linked Hypophosphatemia·Matched via name phrase
Observational and natural-history studies
15 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT07607600·NOT YET RECRUITING·Treatment Patterns, Biochemical Profiles and Clinical Outcomes in Adults With X-Linked Hypophosphatemia
Not reviewed·Conditions: X-linked Hypophosphatemia (XLH)·Matched via name phrase
- NCT07183579·RECRUITING·Effective Dosing of Burosumab in XLH
Not reviewed·Conditions: X-linked Hypophosphatemia (XLH)·Matched via name phrase
- NCT03193476·RECRUITING·Registry for Patients With X-Linked Hypophosphatemia
Not reviewed·Conditions: X-Linked Hypophosphatemia·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 1 · after dedupe 1 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 1 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (1)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for X-linked hypophosphatemia — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26Likely covered — the policy lists Hypophosphatemic rickets as a category (Group 3), and this condition is a form of it. Confirm eligibility with a Centre of Excellence.
Group 3 — high-cost / lifelong therapy with careful selection
Up to ₹50 lakh per patient
Financial support at notified Centres of Excellence is the figure commonly cited in recent MoHFW/PIB statements. Many Group 3 patients also use the MoHFW voluntary-contribution / crowdfunding portal.
Eligibility and patient selection rules change. Verify with a CoE; the crowdfunding portal is a separate mechanism from CoE funding. Verify
Centres of Excellence (15)
- All India Institute of Medical Sciences (AIIMS) — New Delhi, Delhi
- Maulana Azad Medical College — New Delhi, Delhi
- Sanjay Gandhi Post Graduate Institute of Medical Sciences — Lucknow, Uttar Pradesh
- Post Graduate Institute of Medical Education and Research (PGIMER) — Chandigarh, Chandigarh
- Centre for DNA Fingerprinting & Diagnostics with Nizam’s Institute of Medical Sciences — Hyderabad, Telangana
- King Edward Memorial Hospital — Mumbai, Maharashtra
- Institute of Post-Graduate Medical Education and Research (IPGMER) — Kolkata, West Bengal
- Centre for Human Genetics with Indira Gandhi Hospital — Bengaluru, Karnataka
- Institute of Child Health and Hospital for Children (ICH & HC) — Chennai, Tamil Nadu
- All India Institute of Medical Sciences (AIIMS) — Jodhpur, Rajasthan
- Sree Avittam Thirunal Hospital (SAT), Government Medical College — Thiruvananthapuram, Kerala
- All India Institute of Medical Sciences (AIIMS) — Bhopal, Madhya Pradesh
- Regional Institute of Medical Sciences (RIMS) — Imphal, Manipur
- All India Institute of Medical Sciences (AIIMS) — Patna, Bihar
- Assam Medical College & Hospital — Dibrugarh, Assam
Voluntary contributions / crowdfunding (separate from CoE funding): https://rarediseases.mohfw.gov.in/
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("X-linked hypophosphatemia" OR "X-linked hypophosphatemic rickets" OR "X-linked dominant hypophosphatemic rickets" OR "X-linked hereditary hypophosphatemic rickets" OR "hereditary hypophosphatemic rickets, X-linked" OR "hypophosphatemic rickets, X-linked" OR "hypophosphatemic rickets, X-linked dominant, X-linked dominant" OR "rickets, vitamin D-resistant" OR "vitamin D-resistant rickets, X-linked") OR ("PHEX" OR "PHEX syndrome" OR "PHEX-related")ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"X-linked hypophosphatemia" OR "X-linked hypophosphatemic rickets" OR "X-linked dominant hypophosphatemic rickets" OR "X-linked hereditary hypophosphatemic rickets" OR "hereditary hypophosphatemic rickets, X-linked" OR "hypophosphatemic rickets, X-linked" OR "hypophosphatemic rickets, X-linked dominant, X-linked dominant" OR "rickets, vitamin D-resistant" OR "vitamin D-resistant rickets, X-linked"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 29 interventional · 15 observational · 1 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: XLH
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T03:28:01.535Z
